B. Löwenberg

发表

Introduction of the human interleukin-6 (IL-6) receptor in murine IL-3-dependent hematopoietic cells restores responsiveness to IL-6.

R. V. van Gurp, I. Touw, P. Schipper, 1992, Blood.

Introduction of the human interleukin-6 (IL-6) receptor in murine IL-3- dependent hematopoietic cells restores responsiveness to IL-6

T. Agthoven, P. Schipper, B. Löwenberg, 1992 .

Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients

V. Armstrong, A. Vulto, B. Löwenberg, 2007, Therapeutic drug monitoring.

Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

Bas J. Wouters, R. Verhaak, B. Löwenberg, 2009, Haematologica.

A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects.

B. Löwenberg, B. Wouters, R. Delwel, 2009, Blood.

Acute myeloid leukemia: the challenge of capturing disease variety.

B. Löwenberg, 2008, Hematology. American Society of Hematology. Education Program.

A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

Britta A. M. Bouwman, K. Döhner, H. Döhner, 2014, Cell.

Prognostically useful gene-expression profiles in acute myeloid leukemia.

R. Verhaak, M. Moorhouse, P. J. van der Spek, 2004, The New England journal of medicine.

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

B. Löwenberg, R. Zittoun, S. Suciu, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia

Francine E. Garrett-Bakelman, I. Khrebtukova, Lu Zhang, 2012, PLoS genetics.

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

J. Licht, O. Abdel-Wahab, A. Melnick, 2010, Cancer cell.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

Francine E. Garrett-Bakelman, Anna L. Brown, C. Mason, 2016, Nature Medicine.

A 17-gene stemness score for rapid determination of risk in acute leukaemia

Claude Preudhomme, Peter W. Zandstra, Bob Löwenberg, 2016, Nature.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Bob Löwenberg, Benjamin L Ebert, Pierre Fenaux, 2017, Blood.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Markus G. Manz, Bob Löwenberg, Carlos Graux, 2018, The New England journal of medicine.

PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway

M. Nóbrega, A. Kumar, D. Tenen, 2014, Leukemia.

Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia.

T. Agthoven, R. V. van Gurp, T. V. van Agthoven, 1990, Blood.

Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1

J. Gratama, B. Löwenberg, J. Cornelissen, 2009, Cytometry. Part B, Clinical cytometry.

Hierarchical Bayesian formulations for selecting variables in regression models

Veronika Rockova, Emmanuel Lesaffre, Bob Löwenberg, 2012, Statistics in medicine.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.

B. Löwenberg, 2013, Blood.

Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB‐MYH11 gene fusion

M. Breuning, J. Jansen, B. Löwenberg, 2002, British journal of haematology.

Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis.

Bob Löwenberg, J. Gabert, J. Jansen, 2001, The hematology journal : the official journal of the European Haematology Association.

High-dose daunorubicin in older patients with acute myeloid leukemia.

H. Döhner, P. Sonneveld, E. Vellenga, 2009, The New England journal of medicine.

Cytarabine dose for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2011, The New England journal of medicine.

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age

L. Bullinger, H. Döhner, M. Jongen‐Lavrencic, 2016, Leukemia.

Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia.

P. Sonneveld, B. Löwenberg, F. Leebeek, 2016, Blood.

The impact of abn(17p) and monosomy -5/del(5q) on the prognostic value of the monosomal karyotype in acute myeloid leukemia.

W. van Putten, B. Löwenberg, D. Breems, 2013, Blood.

Blood Spotlight Sense and nonsense of high-dose cytarabine for acute myeloid leukemia

B. Löwenberg, 2012 .

Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for

E. Vellenga, M. Fey, A. Gratwohl, 2011 .

Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum

B. Löwenberg, D. Breems, 2011, Haematologica.

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

E. Vellenga, M. Fey, A. Gratwohl, 2011, Blood.

ID1 and ID2 are retinoic acid responsive genes and induce a G0/G1 accumulation in acute promyelocytic leukemia cells

S. Wageningen, J. Jansen, B. Löwenberg, 2005, Leukemia.

Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676)

M. Berger, J. Jansen, B. Löwenberg, 2000, British journal of haematology.

Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice.

G. Wagemaker, B. Löwenberg, A. Prins, 1995, Leukemia.

Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia.

B. Löwenberg, I. Touw, R. Delwel, 1989 .

A rapid RT-PCR based method to isolate complementary DNA fragments flanking retrovirus integration sites.

B. Löwenberg, R. Delwel, P. Valk, 1997, Nucleic acids research.

Leukemic predisposition of pSca-1/Cb2 transgenic mice.

B. Löwenberg, R. Delwel, P. Valk, 2002, Experimental hematology.

Retroviral Insertions in Evi12, a Novel Common Virus Integration Site Upstream of Tra1/Grp94, Frequently Coincide with Insertions in the Gene Encoding the Peripheral Cannabinoid Receptor Cnr2

N. Copeland, N. Jenkins, B. Löwenberg, 1999, Journal of Virology.

Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation.

F. Dong, B. Löwenberg, I. Touw, 1993, Molecular and cellular biology.

Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia.

A. Veerman, L. Hoefsloot, F. Dong, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Tryptophan 650 of human granulocyte colony-stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for G-CSF-mediated activation of signaling complexes of the p21ras route.

F. Dong, B. Löwenberg, I. Touw, 1996, Blood.

Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia

J. Palmblad, M. Freedman, A. Veerman, 1997, Leukemia.

Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia.

B. Löwenberg, I. Touw, A. Ward, 1998, Blood.

Therapy of Acute Myeloid Leukemia in Adults

B. Löwenberg, 2003 .

Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676).

M. Berger, J. Jansen, B. Löwenberg, 2000 .

How I Treat How I treat the older patient with acute myeloid leukemia

G. Ossenkoppele, B. Löwenberg, 2015 .

How I treat the older patient with acute myeloid leukemia.

G. Ossenkoppele, B. Löwenberg, 2015, Blood.

Autologous hematopoietic stem cell transplantation for autoimmune diseases

J. Finke, J. Snowden, A. Gratwohl, 2005, Bone Marrow Transplantation.

Rapid Emergence of Ciprofloxacin-Resistant Enterobacteriaceae Containing Multiple Gentamicin Resistance-Associated Integrons, the Netherlands

H. Endtz, H. Verbrugh, B. Löwenberg, 2001 .

Rapid emergence of ciprofloxacin-resistant enterobacteriaceae containing multiple gentamicin resistance-associated integrons in a Dutch hospital.

H. Endtz, A. van Belkum, H. Verbrugh, 2001, Emerging infectious diseases.

acute myeloid leukemia MicroRNA expression profiling in relation to the genetic heterogeneity of

M. Jongen‐Lavrencic, S. Sun, B. Löwenberg, 2013 .

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

B. Löwenberg, H. Beverloo, E. van Drunen, 2008, Blood.

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.

A. Melnick, M. Figueroa, J. Greally, 2011, Blood.

The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity

H. Beug, M. von Lindern, B. Löwenberg, 2004, Biological chemistry.

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

P. Sonneveld, H. Kantarjian, G. Martinelli, 2011, Blood.

Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia

P. Sonneveld, H. Kantarjian, G. Martinelli, 2011 .

P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy

P. Sonneveld, J. Lankelma, B. Löwenberg, 2000, Leukemia.

Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Bob Löwenberg, Jurgen R Haanstra, Mathijs A Sanders, 2012, Blood.

A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform.

F. Dong, B. Löwenberg, I. Touw, 1995, Blood.

route for G- CSF-mediated activation of signaling complexes of the p21ras required (G-CSF) receptor, implicated in the activation of JAK2, is also Tryptophan 650 of human granulocyte colony-stimulating factor

F. Dong, B. Löwenberg, I. Touw, 2011 .

Severe Chronic Neutropenia Granulocyte Colony-Stimulating Factor Receptor Gene Associated With Perturbed Granulopoiesis in Mice With a Targeted Mutation in the

B. Löwenberg, I. Touw, A. Ward, 1998 .

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

E. Vellenga, M. Jongen‐Lavrencic, L. Michaux, 2020, Leukemia.

The European Cancer Patient’s Bill of Rights, update and implementation 2016

J. Bergh, M. Piccart, C. la Vecchia, 2016, ESMO Open.

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

S. Armstrong, H. Döhner, G. Garcia-Manero, 2014 .

Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells.

L. Aarden, B. Löwenberg, L. V. van Eijk, 1989, Blood.

1 BACKGROUND AND IMPLEMENTATION PLAN FOR THE EUROPEAN CANCER PATIENT’S BILL OF RIGHTS, 2016 (ARCHIVE) ECC Members

Jan, J. Bergh, M. Piccart, 2017 .

Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.

P. Sonneveld, A. Vekhoff, A. Faussat, 1996, Leukemia.

Reply to ‘Response to proposal for a novel cancer drug pricing model’

B. Löwenberg, C. U. Uyl‐de Groot, 2018, Nature Reviews Clinical Oncology.

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

E. Vellenga, G. Juliusson, M. Höglund, 2021, Blood advances.

Cost analysis of CHOP (‐like) chemotherapy regimens for patients with newly diagnosed aggressive non‐Hodgkin's lymphoma

P. Sonneveld, R. Willemze, B. Löwenberg, 2002, European journal of haematology.

Somatostatin receptor scintigraphy useful in stage I–II Hodgkin's disease: more extended disease identified

R. Valkema, E. Krenning, P. Lugtenburg, 2001, British journal of haematology.

Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RARalpha.

D. Tenen, J. Jansen, B. Löwenberg, 2008, Blood.

Acute promyelocytic leukemia with a PLZF-RARα fusion protein

J. Jansen, B. Löwenberg, 2001 .

Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor.

P. Sonneveld, J. Jansen, B. Löwenberg, 1999, Blood.

Haemopoietic growth factors in acute myeloblastic and lymphoblastic leukaemia.

I. Touw, B. Löwenberg, 1992, Bailliere's clinical haematology.

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

S. Rutella, J. Dipersio, P. Chevallier, 2020, Blood.

Somatostatin analogue scintigraphy of malignant lymphomas

E. Krenning, B. Löwenberg, W. Bakker, 1993, British journal of haematology.

Translational Control of Putative Protooncogene Nm23-M2 by Cytokines via Phosphoinositide 3-Kinase Signaling*

B. Habermann, H. Beug, M. von Lindern, 2004, Journal of Biological Chemistry.

Mutations in N-ras predominate in acute myeloid leukemia.

J. L. Bos, J. Bos, M. V. Vries, 1987, Blood.

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

W. M. Smit, M. Kersten, P. Sonneveld, 2010, Haematologica.

Germline loss of MBD4 predisposes to leukaemia due to a mutagenic cascade driven by 5mC

W. Alexander, A. Roberts, I. Majewski, 2017, bioRxiv.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

E. Vellenga, M. Jongen‐Lavrencic, J. Passweg, 2012, Blood.

Another look at imatinib mesylate.

M. Schellings, Y. Pinto, B. Löwenberg, 2007, The New England journal of medicine.

Randomized induction and post induction therapy in adult patients (≤ 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score ≥ 1.5

E. Vellenga, B. Löwenberg, T. Kovacsovics, 2005 .

Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.

P. Sonneveld, G. Ossenkoppele, W. van Putten, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

M. Labopin, D. Blaise, J. Reiffers, 1997, Blood.

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug.

B. Löwenberg, J. Rowe, 2013, Blood.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

I. Bernstein, E. Estey, M. Berger, 2005, Cancer.

B. Löwenberg, C. Kollman, J. Cornelissen, 2001, Blood.

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.

M. Jongen‐Lavrencic, T. Pabst, G. Ossenkoppele, 2020, Blood advances.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

W. Hiddemann, G. Lenz, G. Sauvageau, 2019, Leukemia.

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG

L. Bullinger, H. Döhner, M. Jongen‐Lavrencic, 2016, Leukemia.

A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC

M. V. van Vliet, B. Löwenberg, P. Valk, 2013, Experimental Hematology & Oncology.

Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.

M. V. van Vliet, B. Löwenberg, P. Valk, 2013, Genetic testing and molecular biomarkers.

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia

K. Wagner, M. Heuser, F. Thol, 2012, British journal of haematology.

Retroviral Integration Mutagenesis in Mice and Comparative Analysis in Human AML Identify Reduced PTP4A3 Expression as a Prognostic Indicator

R. Beekman, V. Rocková, E. Taskesen, 2011, PloS one.

immature acute leukemia with myeloid/T-lymphoid features Genome-wide epigenetic analysis delineates a biologically distinct

A. Melnick, M. Figueroa, J. Greally, 2009 .

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

G. Ossenkoppele, B. Löwenberg, R. Delwel, 2008, Haematologica.

A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML.

Bas J. Wouters, B. Löwenberg, B. Wouters, 2007, Blood.

Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia

Bas J. Wouters, M. Sanders, B. Löwenberg, 2007, Leukemia.

The Common Viral Insertion Site Evi12 Is Located in the 5′-Noncoding Region of Gnn, a Novel Gene with Enhanced Expression in Two Subclasses of Human Acute Myeloid Leukemia

B. Löwenberg, R. Delwel, P. Valk, 2005, Journal of Virology.

Differentiation Blockade : The Role of Transcription Factors in AML

J. Licht, M. Tallman, B. Löwenberg, 2005 .

Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML

G. Peters, P. Sonneveld, W. Graveland, 2002 .

Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16).

J. Reilly, B. Löwenberg, D. Bowen, 2004, Haematologica.

Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5.

A. Hagemeijer, P. Schipper, B. Löwenberg, 1991, Leukemia.

Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, B. Löwenberg, 2000, Haematologica.

Post-remission treatment of acute myelogenous leukemia.

B. Löwenberg, 1995, The New England journal of medicine.

Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.

R. Willemze, C. Haanen, B. Löwenberg, 1989, Blood.

Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis

B. Löwenberg, H. G. Eijk, A. Swaak, 1992, European journal of clinical investigation.

leukemic human megakaryoblasts Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of

F. Herrmann, M. Brach, R. Mertelsmann, 2010 .

Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome.

L. Hoefsloot, B. Löwenberg, I. Touw, 1997, Blood.

Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

P. Sonneveld, E. van den Berg, B. van der Holt, 2004, Leukemia research.

Stimulation of proliferation and differentiation of acute myeloid leukemia cells on a bone marrow stroma in culture.

C. Schölzel, B. Löwenberg, 1985, Experimental hematology.

Clonality analysis of hematopoietic cell lineages in acute myeloid leukemia and translocation (8;21): only myeloid cells are part of the malignant clone

A. Hagemeijer, F. Vandekerckhove, B. Löwenberg, 1997, Leukemia.

A point mutation in the granulocyte colony-stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the overexpression of a novel G-CSF-R isoform.

L. Hoefsloot, F. Dong, B. Löwenberg, 1995, Blood.

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma

J. Baars, P. Sonneveld, E. Vellenga, 1999, British journal of haematology.

leukemia cells and monocytes colony-stimulating factor and interleukin-3 on human acute myeloid Common binding structure for granulocyte macrophage

B. Löwenberg, I. Touw, R. Delwel, 2011 .

Somatostatin and its cyclic octapeptide analog SMS 201-995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia.

E. Krenning, B. Löwenberg, V. Santini, 1995, Leukemia research.

Tumor necrosis factor downregulates granulocyte-colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes.

I. Touw, B. Löwenberg, I. Touw, 1991, The Journal of clinical investigation.

Tumor necrosis factor regulates the expression of granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors on human acute myeloid leukemia cells.

I. Touw, B. Löwenberg, I. Touw, 1991, Blood.

Common binding structure for granulocyte macrophage colony-stimulating factor and interleukin-3 on human acute myeloid leukemia cells and monocytes.

B. Löwenberg, I. Touw, R. Delwel, 1990, Blood.

Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response.

S. Clark, I. Touw, B. Löwenberg, 1989, Blood.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

B. Löwenberg, P. Valk, 2018, The New England journal of medicine.

Retroviral transfer of the multidrug resistance‐1 gene into lineage‐committed and primitive hemopoietic cells

W. Zeller, D. Valerio, B. Löwenberg, 1995, Stem cells.

Translocation (6;9) may be associated with a specific TdT-positive immunological phenotype in ANLL.

A. Hagemeijer, J. V. van Dongen, H. Hooijkaas, 1988, Leukemia.

Internalization‐defective mutants of somatostatin receptor subtype 2 exert normal signaling functions in hematopoietic cells

S. Lamberts, I. Touw, B. Löwenberg, 2001, FEBS letters.

Analysis of the TNF receptors on human leukaemia cells by affinity cross‐linking

I. Touw, B. Löwenberg, I. Touw, 1992, British journal of haematology.

Flt3 Ligand Expands Lymphoid Progenitors Prior to Recovery of Thymopoiesis and Accelerates T Cell Reconstitution after Bone Marrow Transplantation1

F. Staal, E. Wils, H. Spits, 2007, The Journal of Immunology.

Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.

P. Sonneveld, B. Löwenberg, P. T. Boekhorst, 1993, Leukemia.

CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

V. V. D. van der Velden, M. Jongen‐Lavrencic, T. Pabst, 2018, Leukemia.

Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia

T. Pabst, G. Schuurhuis, G. Ossenkoppele, 2014, PloS one.

Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation

L. Hoefsloot, F. Dong, B. Löwenberg, 1993, Molecular and cellular biology.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

E. Vellenga, M. Jongen‐Lavrencic, M. Vekemans, 2019, Blood.

Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes

N. Rooijen, G. Wagemaker, B. Löwenberg, 1997, Leukemia.

Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells.

S. Mancham, B. Löwenberg, R. Delwel, 1997, Blood.

Involvement of tumor necrosis factor (TNF) receptors p55 and p75 in TNF responses of acute myeloid leukemia blasts in vitro.

I. Touw, B. Löwenberg, R. Delwel, 1992, Blood.

The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro.

H. Beug, P. Steinlein, M. von Lindern, 1999, Blood.

EBV reactivation and lymphoproliferative disease transplantation may identify patients at very high risk for progressive lymphocytes after partially T-depleted allogeneic stem cell specific CD8+ T -- Impaired recovery of Epstein-Barr virus (EBV)

D. Baarle, F. Miedema, E. Pamer, 2013 .

Btk Is Required for an Efficient Response to Erythropoietin and for SCF-controlled Protection against TRAIL in Erythroid Progenitors

H. Beug, M. von Lindern, W. Ellmeier, 2004, The Journal of experimental medicine.

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

M. Jongen‐Lavrencic, T. Pabst, G. Ossenkoppele, 2022, Blood.

Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.

P. Sonneveld, B. Löwenberg, P. T. Boekhorst, 1994, Leukemia.

Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system

G. Wagemaker, S. Clark, B. Löwenberg, 1988 .

Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony-forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-alpha which synergizes with IL-3 or granulocyte-macrophage colony-stimulating factor.

I. Touw, B. Löwenberg, R. Delwel, 1990, Leukemia.

Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro.

G. Wagemaker, I. Touw, B. Löwenberg, 1987, Blood.

Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants.

B. van der Holt, H. Spits, B. Löwenberg, 2003, Blood.

Protein Kinase C α Controls Erythropoietin Receptor Signaling*

H. Beug, M. von Lindern, P. Willems, 2000, The Journal of Biological Chemistry.

Candida krusei Transmission among Hematology Patients Resolved by Adapted Antifungal Prophylaxis and Infection Control Measures

H. Endtz, A. van Belkum, H. Verbrugh, 2006, Journal of Clinical Microbiology.

Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia.

G. Wagemaker, B. Löwenberg, R. Ploemacher, 1996, Blood.

Granulocyte-macrophage colony-stimulating factor receptors alter their binding characteristics during myeloid maturation through up-regulation of the affinity converting beta subunit (KH97).

B. Löwenberg, I. Touw, R. Delwel, 1993, The Journal of biological chemistry.

Membrane receptors for interleukin 2 on hematopoietic precursors in chronic myeloid leukemia.

I. Touw, B. Löwenberg, R. Delwel, 1987, Blood.

older age : a randomized phase 2 trial of the Dutch-Belgian Cooperative Addition of bevacizumab to chemotherapy in acute myeloid leukemia

E. Vellenga, K. Montfort, M. Jongen‐Lavrencic, 2012 .

Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.

L. Hoefsloot, B. Löwenberg, B. Backx, 1996, Leukemia.

Myelodysplastic syndromes standardized response criteria: further definition.

B. Cheson, P. Greenberg, H. Kantarjian, 2001, Blood.

Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia.

B. Löwenberg, I. Touw, R. Delwel, 1989, Blood.

Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome.

B. Löwenberg, B. Lowenberg, B. Backx, 1992, Blood.

Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid.

R. V. van Gurp, I. Touw, B. Löwenberg, 1991, Leukemia research.

Interleukin-1 alpha also induces granulocyte-macrophage colony-stimulating factor in immature normal bone marrow cells.

K. Kaushansky, P. Schipper, B. Löwenberg, 1990, Blood.

Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release.

K. Kaushansky, B. Löwenberg, R. Delwel, 1989, Blood.

Further results in understanding the subpopulation structure of AML: clonogenic cells and their progeny identified by differentiation markers.

B. Löwenberg, J. Bauman, B. Lowenberg, 1985, Blood.

Production of T lymphocyte colony-forming units from precursors in human long-term bone marrow cultures.

I. Touw, B. Löwenberg, 1984, Blood.

Is the Basis of Cleaning Autologous Bone Marrow Transplants in Leukemia Strong Enough

B. Löwenberg, 1984 .

On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes.

B. Löwenberg, R. Wouters, 1984, Blood.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

W. M. Smit, M. Kersten, P. Sonneveld, 2008, Blood.

CD20 and CD40 mediated mitogenic responses in B‐lineage acute lymphoblastic leukaemia

B. Löwenberg, I. Touw, F. Smiers, 1996, British journal of haematology.

Chronic myeloid leukemia with permanent disappearance of the Ph1 chromosome and development of new clonal subpopulations.

A. Hagemeijer, B. Löwenberg, J. Abels, 1979, Blood.

Running head: TIPIFARNIB IN REFRACTORY OR RELAPSED AML

J. Reiffers, J. Lancet, X. Thomas, 2007 .

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

H. Keizer, E. Vellenga, E. de Vries, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Costs and Quality of Life with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Antineoplastic Therapy—Related Febrile Neutropenia

E. Vellenga, F. Rutten, B. Löwenberg, 1997, PharmacoEconomics.

Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.

P. Sonneveld, J. Lankelma, G. Ossenkoppele, 1996, Blood.

Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs).

B. Löwenberg, R. Delwel, V. Santini, 1990, Leukemia research.

Acute lymphoblastic leukemia and non-Hodgkin's lymphoma of T lineage: colony-forming cells retain growth factor (interleukin 2) dependence.

B. Löwenberg, I. Touw, R. Delwel, 1986, Blood.

Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward

A. van Belkum, H. Verbrugh, B. Löwenberg, 1996, Journal of clinical microbiology.

The proliferative response of B cell chronic lymphocytic leukemia to interleukin 2: functional characterization of the interleukin 2 membrane receptors.

I. Touw, B. Löwenberg, L. Dorssers, 1987, Blood.

Interleukin 2 stimulates chronic lymphocytic leukemia colony formation in vitro.

I. Touw, B. Löwenberg, I. Touw, 1985, Blood.

Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.

W. Hop, P. Lugtenburg, A. Vulto, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.

G. Morgan, P. Sonneveld, U. Dührsen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2.

I. Touw, B. Löwenberg, I. Touw, 2001, The hematology journal : the official journal of the European Haematology Association.

Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells.

H. Mano, M. von Lindern, B. Löwenberg, 2000, Blood.

prognosis of adult acute myeloid leukemia Relation between CXCR-4 expression, Flt3 mutations and unfavourable

B. Löwenberg, E. Rombouts, R. Ploemacher, 2013 .

Acute myeloid leukemia and the position of autologous stem cell transplantation.

B. Löwenberg, D. Breems, 2007, Seminars in hematology.

Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia

B. Löwenberg, D. Breems, Dimitri A. Breems, 2005, British journal of haematology.

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

B. Löwenberg, E. Rombouts, R. Ploemacher, 2004, Blood.

Relation between CXCR4 expression , Flt 3 mutations , and unfavorable prognosis of adult acute myeloid leukemia

B. Löwenberg, E. Rombouts, R. Ploemacher, 2004 .

Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene

W. V. Putten, B. Löwenberg, W. Rombouts, 2001, Leukemia.

Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors.

B. Löwenberg, I. Touw, B. Backx, 1993, Leukemia.

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Bob Löwenberg, Jason Gotlib, Yixin Wang, 2007, Blood.

The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation.

P. Sonneveld, A. Hagemeijer, W. van Putten, 1991, Bone marrow transplantation.

Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide

M. Labopin, R. Willemze, G. Meloni, 1991 .

PHA-induced colony formation in acute non-lymphocytic and chronic myeloid leukemia.

A. Hagemeijer, B. Löwenberg, K. Swart, 1980, Leukemia research.

Treatment of the elderly patient with acute myeloid leukaemia.

B. Löwenberg, 1996, Bailliere's clinical haematology.

The long road: improving outcome in elderly "unfit" AML?

B. Löwenberg, G. Huls, 2020, Blood.

Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual‐color fluorescence in situ hybridization and confocal laser scanning microscopy

A. Houtsmuller, W. van Putten, B. Löwenberg, 1999, Genes, chromosomes & cancer.

Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.

P. Sonneveld, A. Hagemeijer, B. Löwenberg, 1993, Blood.

The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

G. Peters, P. Sonneveld, W. Graveland, 2004, Blood.

a study of 319 de novo AML patients High EVI1 expression predicts poor survival in acute myeloid leukemia

P. Sonneveld, G. Ossenkoppele, G. Verhoef, 2013 .

Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.

B. Ebert, H. Döhner, R. Larson, 2022, Blood.

Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage.

A. Hagemeijer, B. Löwenberg, K. Groeneveld, 1995, Leukemia.

RUNX1 GERMLINE VARIANTS IN RUNX1-MUTANT AML: HOW FREQUENT?

M. Raaijmakers, B. Löwenberg, P. Valk, 2020, Blood.

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML

L. Bullinger, H. Döhner, M. Jongen‐Lavrencic, 2013, Leukemia.

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

E. Vellenga, M. Jongen‐Lavrencic, M. Vekemans, 2021, Cancers.

A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia.

G. Morgan, P. Sonneveld, M. Jongen‐Lavrencic, 2008 .

The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study

A. Ganser, B. Löwenberg, F. Traina, 2017 .

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

F. Appelbaum, T. Bochtler, U. Hegenbart, 2013, Blood.

Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).

P. Sonneveld, W. van Putten, B. Löwenberg, 1994, Leukemia.

Acute myeloid leukemia [4] (multiple letters)

S. Glaser, B. Löwenberg, C. Clarke, 2000 .

Treatment of acute myelogenous leukaemia

B. Löwenberg, 1997, Journal of internal medicine. Supplement.

High dose therapy for acute myelocytic leukemia treatment strategy: what is the choice?

B. Löwenberg, N. Gorin, K. Dicke, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Practical aspects and diagnostic significance of in vitro manipulation of progenitors in human acute myeloid and lymphoid leukaemia.

I. Touw, B. Löwenberg, 1991, Bailliere's Clinical Haematology.

Different repopulation kinetics of erythroid (BFU‐E), myeloid (CFU‐GM) and T lymphocyte (TL‐CFU) progenitor cells after autologous and allogeneic bone marrow transplantation

A. Hagenbeek, E. Vellenga, B. Löwenberg, 1987, British journal of haematology.

Autologous Bone Marrow Transplantation in Acute Myeloblastic Leukemia (AML): In Vitro Studies to Detect Minimal Disease in Remission Marrow

B. Löwenberg, R. Delwel, 1987 .

Treatment of patients with acute myeloid leukemia in first remission with marrow ablative therapy and autologous bone marrow transplantation.

A. Hagenbeek, G. Wagemaker, B. Löwenberg, 1987, Haematology and blood transfusion.

Minimal Residual Disease in Acute Leukemia 1986

A. Hagenbeek, B. Löwenberg, 1986, Developments in Oncology.

Synergistic effects between GM-CSF and G-CSF or M-CSF on highly enriched human marrow progenitor cells.

P. Schipper, B. Löwenberg, B. Backx, 1990, Leukemia.

Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?

A. Hagenbeek, E. Vellenga, M. Fey, 1999, Bone Marrow Transplantation.

Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

G. Juliusson, J. Passweg, K. Porkka, 2022, Frontiers in Oncology.

Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.

C. Chastang, M. Fey, P. Fenaux, 1995, Leukemia & lymphoma.

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

M. Jongen‐Lavrencic, M. Gregor, G. Ossenkoppele, 2022, Leukemia.

Managing therapy in older adult patients with acute myeloid leukemia.

B. Löwenberg, 2001, Seminars in hematology.

Minimal residual disease in chronic myeloid leukemia.

B. Löwenberg, 2003, The New England journal of medicine.

Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.

B. Löwenberg, 2008, The New England journal of medicine.

Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia

J. Esteve, M. Berger, M. Tallman, 2001 .

Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment

P. Sonneveld, B. Löwenberg, J. Cornelissen, 1998, Bone Marrow Transplantation.

An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

A. Hagemeijer, H. Kluin-Nelemans, B. Löwenberg, 1998, The Journal of clinical investigation.

Feeder cell requirements for leukemia cell colony formation in cultures supplemented with phytohemagglutinin.

B. Löwenberg, K. Swart, 1984, Cancer research.

Karyotypically distinct subpopulations in acute leukemia with specific growth requirements.

A. Hagemeijer, B. Löwenberg, K. Swart, 1982, Blood.

In vitro colony growth of acute myelogenous leukemia.

A. Cork, B. Löwenberg, G. Spitzer, 1976, Hamatologie und Bluttransfusion.

Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro.

B. Löwenberg, H. Schellekens, M. D. de Vries, 1978, Cancer research.

Application of myeloid growth factors in the treatment of acute myeloid leukemia

B. Löwenberg, W. Terpstra, Bob Löwenberg, 1997, Leukemia.

Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research

P. Sonneveld, E. Vellenga, A. Gratwohl, 2005, British journal of haematology.

Cytokines and Growth Factors in Blood Transfusion

B. Löwenberg, C. S. Sibinga, P. C. Das, 1997 .

Splenectomy for the treatment of thrombotic thrombocytopenic purpura

B. Löwenberg, M. Kappers-Klunne, A. Brand, 2005, British journal of haematology.

NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia

A. Ganser, F. Lo‐Coco, R. Ribeiro, 2020, Scientific Reports.

Somatostatin induces migration of acute myeloid leukemia cells via activation of somatostatin receptor subtype 2

I. Touw, B. Löwenberg, J. Hofland, 2001, Leukemia.

Somatostatin and the immune and haematopoetic system; a review

E. Krenning, S. Lamberts, J. Reubi, 1994, European journal of clinical investigation.

Quantification of newly developed T cells in mice by real-time quantitative PCR of T-cell receptor rearrangement excision circles.

J. V. van Dongen, J. Meijerink, B. Löwenberg, 2002, Experimental hematology.

Paradoxical effects of interleukin‐10 on the maturation of murine myeloid dendritic cells

K. Karimi, B. Löwenberg, J. Cornelissen, 2003, Immunology.

The value of alloantibody detection in predicting response to HLA‐matched platelet transfusions

B. Löwenberg, M. Kappers-Klunne, M. Levin, 2004, British journal of haematology.

A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions

B. Löwenberg, K. Sintnicolaas, 1996, British journal of haematology.

Platelet transfusion and alloimmunization [letter]

B. Löwenberg, K. Sintnicolaas, J. Velden, 1982 .

Proliferative response of highly purified B chronic lymphocytic leukemia cells in serum free culture to interleukin-2 and tumor necrosis factors alpha and beta.

I. Touw, T. V. van Agthoven, B. Löwenberg, 1989, Leukemia research.

Common and pre-B acute lymphoblastic leukemia cells express interleukin 2 receptors, and interleukin 2 stimulates in vitro colony formation.

I. Touw, B. Löwenberg, R. Delwel, 1985, Blood.

Activated RAS Oncogenes in Acute Leukemia

J. Bos, M. V. Vries, A. V. D. Eb, 1986 .

Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123.

D. Valerio, B. Löwenberg, S. Fruehauf, 1996, Human gene therapy.

Rapid Simultaneous Screening of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood

J. Jansen, B. Löwenberg, B. A. Reijden, 1998 .

The expression of the Peripheral Cannabinoid receptor on cells of the immune system and Non-Hodgkin's lymphomas

P. Sonneveld, B. Löwenberg, R. Delwel, 2007, Leukemia & lymphoma.

Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status 1

P. Sonneveld, J. Laman, B. Löwenberg, 2004, The Journal of Immunology.

Depending on Receptor Activation Status Cannabinoid Receptor in Lymphoid Tissues Distinct Expression Profiles of the Peripheral

P. Sonneveld, J. Laman, B. Löwenberg, 2004 .

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

M. Jongen‐Lavrencic, G. Ossenkoppele, M. Manz, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

colony-forming cells retain growth factor (interleukin 2) dependence Acute lymphoblastic leukemia and non-Hodgkin's lymphoma of T lineage:

B. Löwenberg, I. Touw, R. Delwel, 2011 .

Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies.

D. Campana, H. Kluin-Nelemans, B. Löwenberg, 2009, Scandinavian journal of haematology.

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

B. Löwenberg, J. Cloos, D. Cucchi, 2021, Blood advances.

Developments in T-cell depletion of allogeneic stem cell grafts.

B. Löwenberg, J. Cornelissen, Jan J. Cornelissen, 2000, Current opinion in hematology.

Vim-2, candidate monoclonal antibody for purging autologous marrow grafts in acute myeloblastic leukaemia.

B. Löwenberg, R. Delwel, F. Bot, 1987, Bone marrow transplantation.

The relevance of somatostatin receptor expression in malignant lymphomas.

E. Krenning, S. Lamberts, B. Löwenberg, 1996, Metabolism: clinical and experimental.

Somatostatin receptor scintigraphy in cutaneous malignant lymphomas.

E. Krenning, B. Löwenberg, F. Heule, 1996, Journal of the American Academy of Dermatology.

Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease

E. Krenning, B. Löwenberg, J. C. Reubi, 1996, British journal of haematology.

Hematopoietic growth factor receptors: structure variations and alternatives of receptor complex formation in normal hematopoiesis and in hematopoietic disorders.

F. Dong, I. Touw, B. Löwenberg, 1995, Leukemia.

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials

M. Vignetti, G. Leone, F. Baron, 2020, Cancers.

Mutant Wilms’ tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD)

B. Löwenberg, S. Abbas, P. Valk, 2010, Leukemia.

Stem Cells Initiate Leukemia in Immunodeficient Mice, But Spares Normal Hemopoietic Factor Eliminates Acute Myeloid Leukemia Cells With the Potential to Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating

B. Löwenberg, R. Kreitman, H. Rozemuller, 2013 .

Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation

C. Boucher, B. van der Holt, J. Gratama, 2001, British journal of haematology.

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

B. Fox, J. Dipersio, J. Wigginton, 2017 .

Influence of genetic resistance and silica particles on survival after bone marrow transplantation.

B. Löwenberg, D. V. van Bekkum, H. Vriesendorp, 1976, Transplantation Proceedings.

No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557.

A. Hagenbeek, H. Kluin-Nelemans, B. Löwenberg, 1984, Leukemia research.

No stimulative effect of adipocytes on hematopoiesis in long-term human bone marrow cultures.

I. Touw, B. Löwenberg, 1983, Blood.

Graft-versus-host disease following transplantation of 'one log' versus 'two log' T-lymphocyte-depleted bone marrow from HLA-identical donors.

A. Hagenbeek, G. Wagemaker, B. Löwenberg, 1986, Bone marrow transplantation.

Prognostic factors in acute myeloid leukaemia.

B. Löwenberg, 2001, Best practice & research. Clinical haematology.

Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.

P. Sonneveld, A. Hagemeijer, B. Löwenberg, 1993, Blood.

Allografting as Consolidative Immunotherapy for Older Patients with AML in Complete Remission Using Low Dose TBI, PBSC Infusion And Post- Transplant Immunosuppression With Cyclosporine And Mycophenolate

D. Niederwieser, B. Löwenberg, 2002 .

Acute myeloid leukaemia with +i(12p) shortly after treatment of mediastinal germ cell tumour

A. Hagemeijer, B. Löwenberg, K. Lom, 1994, British journal of haematology.

Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.

B. Löwenberg, I. Touw, F. Smiers, 1996, Leukemia.

RAS mutations are frequent events in AML, with their report- ed frequency being up to 30%.

J. Reilly, B. Löwenberg, D. Bowen, 2004 .

International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

M. Loh, E. Estey, M. Cazzola, 2022, Blood.

Patterns of acute myeloid leukemia colony growth in response to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF).

E. Vellenga, B. Löwenberg, I. Touw, 1987, Experimental hematology.

Monitoring cytomegalovirus IE‐1 and pp65‐specific CD4+ and CD8+ T‐cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations

B. van der Holt, B. Löwenberg, H. Niesters, 2008, Cytometry. Part B, Clinical cytometry.

Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: results of a pilot study in four patients.

A. Hagenbeek, B. Löwenberg, W. Sizoo, 1983, Leukemia research.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

E. Estey, H. Döhner, T. Naoe, 2019, Blood.

P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia.

P. Sonneveld, E. Vellenga, G. Ossenkoppele, 1999 .

Lymphocyte recovery following allogeneic stem cell transplantation: New possibilities for improvement

B. Löwenberg, J. Cornelissen, J. Gratama, 2002 .

Dexamethasone does not counteract the response of acute promyelocytic leukaemia cells to all‐trans retinoic acid

J. Jansen, B. Löwenberg, C. Erpelinck-Verschueren, 1999, British journal of haematology.

Transplantation of non‐purified autologous bone marrow in patients with AML in first remission

A. Hagenbeek, G. Wagemaker, B. Löwenberg, 1984, Cancer.

Gene transactivation without direct DNA binding deﬁnes a novel gain-of-function for PML-RAR (cid:1)

D. Tenen, B. V. D. Reijden, J. Jansen, 2008 .

Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.

P. Sonneveld, B. Löwenberg, K. Nooter, 1995, Leukemia.

analysis benefits for whom? results of a HOVON/SAKK donor versus no donor remission acute myeloid leukemia in young and middle aged adults: Myeloablative HLA-identical sibling stem cell transplantation in first

M. Fey, A. Gratwohl, B. Löwenberg, 2013 .

Phenotyping of acute myelocytic leukemia (AML) progenitors: an approach for tracing minimal numbers of AML cells among normal bone marrow.

R. V. van Gurp, I. Touw, B. Löwenberg, 1988, Leukemia.

Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.

B. Löwenberg, C. Erpelinck, R. Delwel, 2003, Experimental hematology.

IL-7-mediated protection against minor-antigen-mismatched allograft rejection is associated with enhanced recovery of regulatory T cells.

E. Wils, H. Spits, B. Löwenberg, 2007, Haematologica.

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

H. Döhner, M. Tallman, C. Dinardo, 2017 .

Towards Detection of Minimal Disease: Discrimination of AML Precursors from Normal Myeloid Precursors using a Combination of Surface Markers

B. Löwenberg, I. Touw, R. Delwel, 1986 .

Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia.

B. Löwenberg, J. Cornelissen, 2005, Hematology. American Society of Hematology. Education Program.

Cell to cell contact enhances the proliferation of acute myeloid leukemia (AML) cells in vitro without an apparent role of adhesion glycoproteins LFA1, MAC1 and P150-95.

I. Touw, B. Löwenberg, I. Touw, 1989, Leukemia research.

Sustainability and affordability of cancer drugs: a novel pricing model

Bob Löwenberg, B. Löwenberg, C. U. Uyl‐de Groot, 2018, Nature Reviews Clinical Oncology.

Reply to ‘Economic comments on proposal for a novel cancer drug pricing model’

B. Löwenberg, C. U. Uyl‐de Groot, 2018, Nature Reviews Clinical Oncology.

Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein.

J. Jansen, B. Löwenberg, 2001, Seminars in hematology.

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

Augustin Ferrant, Bob Löwenberg, Alois Gratwohl, 2003, The New England journal of medicine.

B. Löwenberg, M. Maccarrone, R. Delwel, 2004 .

Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice.

B. Löwenberg, R. Delwel, P. Valk, 2000, Virology.

Therapeutic advances in acute myeloid leukemia.

B. Löwenberg, A. Burnett, M. Wetzler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

E. Vellenga, M. Fey, M. Jongen‐Lavrencic, 2014, Leukemia.

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.

H. Döhner, P. Sonneveld, E. Vellenga, 2010, Blood.

Prognostic index for adult patients with acute myeloid leukemia in first relapse.

Bob Löwenberg, E. Vellenga, G. Ossenkoppele, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed

H. Putter, B. van der Holt, J. Passweg, 2021, Cancer medicine.

Towards precision medicine for AML

H. Döhner, A. Wei, B. Löwenberg, 2021, Nature Reviews Clinical Oncology.

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Bob Löwenberg, Elihu H. Estey, Megan Othus, 2014, Leukemia.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Bob Löwenberg, Carlos Graux, Nancy Boeckx, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

I. Bernstein, E. Estey, I. Bernstein, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Including historical data in the analysis of clinical trials: Is it worth the effort?

Yvette van Norden, Joost van Rosmalen, Emmanuel Lesaffre, 2017, Statistical methods in medical research.

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.

Bob Löwenberg, Jakob Passweg, Carlos Graux, 2012, Blood.

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.

M A Boogaerts, A. Hagenbeek, E. Vellenga, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phagocytic plasma cells in a patient with multiple myeloma.

A. Hagemeijer, B. Löwenberg, K. De Leeuw, 1995, The Netherlands journal of medicine.

Phase II study of lomustine, cytarabine, mitoxantrone, and prednisone (CAMP) combination chemotherapy for doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphoma.

A. Hagenbeek, G. Verhoef, B. Löwenberg, 1990, Seminars in oncology.

A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.

B. van der Holt, J. Gratama, B. Löwenberg, 2005, Experimental hematology.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

B. van der Holt, J. Gratama, A. Osterhaus, 2002, Blood.

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.

V. Kuenen-Boumeester, S. Henzen‐Logmans, S. Henzen‐Logmans, 2000, Blood.

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

B. van der Holt, A. Osterhaus, B. Löwenberg, 2001, Blood.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

C. Bloomfield, E. Estey, W. Hiddemann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Management in paraproteinemia].

P. Sonneveld, B. Löwenberg, 1992, Nederlands tijdschrift voor geneeskunde.

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.

C. Tournay, C. Lamers, J. Gratama, 2001, Blood.

Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study.

B. Löwenberg, J. Cornelissen, L. Verdonck, 2003, Experimental hematology.

DELAYED ALLOIMMUNISATION BY RANDOM SINGLE DONOR PLATELET TRANSFUSIONS A Randomised Study to Compare Single Donor and Multiple Donor Platelet Transfusions in Cancer Patients with Severe Thrombocytopenia

B. Löwenberg, J. Abels, K. Sintnicolaas, 1981, The Lancet.

P. Sonneveld, E. Vellenga, B. van der Holt, 2007, Annals of Hematology.

Acute myeloid leukemia.

J. Downing, B. Löwenberg, A. Burnett, 1999, The New England journal of medicine.

Clonogenic cells in acute myeloblastic leukemia.

J. Griffin, B. Löwenberg, J D Griffin, 1986, Blood.

Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors.

B. Löwenberg, B. Backx, L. Broeders, 1991, Leukemia.

Anaemia of chronic disease in rheumatoid arthritis

B. Löwenberg, H. G. Eijk, A. Swaak, 1990, Rheumatology International.

Enhancement of erythropoietin-stimulated cell proliferation by Anandamide correlates with increased activation of the mitogen-activated protein kinases ERK1 and ERK2.

M. von Lindern, B. Löwenberg, R. Delwel, 2000, The hematology journal : the official journal of the European Haematology Association.

STAT3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27Kip1

B. Löwenberg, I. Touw, A. Ward, 2000, Oncogene.

A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.

R. Willemze, C. Haanen, B. Löwenberg, 1990, Haematology and blood transfusion.

Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia.

W. van Putten, B. Löwenberg, I. Touw, 1993, The New England journal of medicine.

Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.

K. Welte, F. Dong, R. Brynes, 1995, The New England journal of medicine.

Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

K. Döhner, H. Döhner, S. Gröschel, 2015, Blood.

Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias

B. Löwenberg, S. Abbas, P. Valk, 2008, Haematologica.

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

Pu Zhang, Bob Löwenberg, Bas J. Wouters, 2007, Blood.

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Bob Löwenberg, André G Uitterlinden, Maarten A. Bijl, 2005, Blood.

Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

J. Reilly, B. Löwenberg, P. Valk, 2003, British journal of haematology.

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

Bob Löwenberg, Daniel G Tenen, Ruud Delwel, 2003, The hematology journal : the official journal of the European Haematology Association.

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

B. Cheson, P. Greenberg, H. Kantarjian, 2000, Blood.

Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3.

H. Burger, G. Wagemaker, B. Löwenberg, 1987, Gene.

Fetal liver cell transplantation : role and nature of the fetal haemopoietic stem cell

B. Löwenberg, 1975 .

The incidence of herpes zoster in patients with Hodgkin's disease an analysis of prognostic factors

G. Giacco, S. Dische, M. Durand, 1985, Cancer.

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

R. Schlenk, J. Sierra, M. Mohty, 2012, Nature Reviews Clinical Oncology.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia

B. Löwenberg, R. Delwel, M. Tang, 2005, Oncogene.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.

J. Baars, P. Sonneveld, B. van der Holt, 2009, Blood.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

S. Armstrong, G. Garcia-Manero, M. Tallman, 2018, Blood.

status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to

E. Vellenga, M. Fey, G. Ossenkoppele, 2013 .

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

P. Sonneveld, E. Vellenga, B. van der Holt, 2005, Blood.

The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis

E. Vellenga, M. Fey, P. Piccaluga, 2022 .

Effects of fibroblasts on the growth of erythroid progenitor cells in vitro.

B. Löwenberg, F. Ajmar, K. Dicke, 1977, Experimental hematology.

An assay for serum cytotoxicity against erythroid precursor cells in pure red cell aplasia.

B. Löwenberg, R. Ghio, 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

Hematopoietic growth factors and in vitro growth of human acute myeloblastic leukemia.

I. Touw, B. Löwenberg, R. Delwel, 1990, Critical reviews in oncology/hematology.

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Bob Löwenberg, M. Jongen‐Lavrencic, S. Sun, 2008, Blood.

Concentrations of ciclosporin in allogeneic bone marrow recipients

A. Hagenbeek, P. Sonneveld, B. Löwenberg, 1987, Blut.

The genes encoding the peripheral cannabinoid receptor and alpha-L-fucosidase are located near a newly identified common virus integration site, Evi11

N. Copeland, D. Gilbert, N. Jenkins, 1997, Journal of virology.

Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal.

M. Heuser, A. Weng, F. Kuchenbauer, 2009, Blood.

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

Bob Löwenberg, F. Lo‐Coco, M. Sanz, 2009, Current opinion in oncology.

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Bob Löwenberg, Ruud Delwel, P. Sonneveld, 2003, Blood.

Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene

B. Löwenberg, W. Rombouts, R. Ploemacher, 2000, Leukemia.

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Fabien Campagne, Lucy Skrabanek, Bob Löwenberg, 2010, Cancer cell.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

T. Haferlach, R. Hills, S. Schnittger, 2015, Blood.

Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis

W. Hop, R. Hintzen, B. Löwenberg, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Minimal Residual Disease in Acute Leukemia

A. Hagenbeek, B. Löwenberg, 1984, Developments in Oncology.

Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations

J. V. van Galen, J. Peeters, M. Sanders, 2014, Haematologica.

PBX3 is an important cofactor of HOXA9 in leukemogenesis.

J. Rowley, L. Bullinger, K. Döhner, 2013, Blood.

AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance.

E. Vellenga, B. Löwenberg, R. Delwel, 2009, Blood.

In situ hybridization on May-Grünwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities.

A. Hagemeijer, B. Löwenberg, K. van Lom, 1993, Blood.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

W. van Putten, B. Löwenberg, S. Abbas, 2010, Blood.

M. Sanz, G. Ossenkoppele, S. Brunet, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

W. M. Smit, B. van der Holt, G. Verhoef, 2006, Annals of Hematology.

Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites

Bob Löwenberg, Ruud Delwel, B. Löwenberg, 2002, Oncogene.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

S. Fröhling, W. Alexander, A. Roberts, 2018, Blood.

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

E. Vellenga, A. Gratwohl, J. Passweg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features.

Lucy Skrabanek, Bob Löwenberg, Bas J. Wouters, 2009, Blood.

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

A. Hagemeijer, W. van Putten, B. Löwenberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hematopoietic growth factors and their receptors in acute leukemia.

I. Touw, B. Löwenberg, I. Touw, 1993, Blood.

The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner.

B. Löwenberg, M. Maccarrone, R. Delwel, 2004, Blood.

Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol.

B. Löwenberg, M. Maccarrone, A. Finazzi-Agrò, 2002, Blood.

Acute lymphoblastic leukaemia in adults: Immunological subtypes and clinical features at presentation

G. Ossenkoppele, B. Löwenberg, J. Kluin-Nelemans, 1993, Annals of Hematology.

Cytogenetic clonality analysis: typical patterns in myelodysplastic syndrome and acute myeloid leukaemia

A. Hagemeijer, F. Vandekerckhove, B. Löwenberg, 1996, British journal of haematology.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

L. Bullinger, M. Heuser, F. Thol, 2019, Blood.

Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors.

M. von Lindern, B. Löwenberg, S. Waltz, 2004, Blood.

Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.

A. Hagenbeek, B. Löwenberg, R. Kreitman, 1997, Blood.

Differential Regulation of Foxo3a Target Genes in Erythropoiesis

R. Verhaak, T. Mak, H. Beug, 2007, Molecular and Cellular Biology.

Recombinant hematopoietic growth factors fail to induce a proliferative response in precursor B acute lymphoblastic leukemia.

A. Hagemeijer, I. Touw, T. V. van Agthoven, 1989, Leukemia.

Epstein-Barr virus ( EBV ) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation

J. Willem, A. Osterhaus, B. Löwenberg, 2002 .

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

Veronika Rockova, Bob Löwenberg, Ruud Delwel, 2012, Blood.

with silenced CEBPA and mutations in NOTCH1 Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia

Bas J. Wouters, R. Verhaak, Y. Yashiro‐Ohtani, 2013 .

PBX 3 is an important cofactor of HOXA 9 in leukemogenesis *

J. Rowley, L. Bullinger, K. Döhner, 2013 .

FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1

H. Beug, P. Steinlein, A. Kolbus, 2004, The Journal of cell biology.

Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.

K. Döhner, R. Schlenk, H. Döhner, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

disease following T-cell-depleted SCT cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem

B. Löwenberg, F. Frassoni, H. Niesters, 2010 .

3. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation.

B. Löwenberg, F. Frassoni, J. Cornelissen, 2001 .

Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all‐trans retinoic acid and anthracycline‐based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study

A. Ganser, S. Schrier, F. Lo‐Coco, 2014, British journal of haematology.

PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.

B. Torbett, T. Haferlach, M. Tschan, 2012, Blood.

Retinoic acid receptor fusion proteins: friend or foe

J. Jansen, B. Löwenberg, M. D. Ridder, 2000, Molecular and Cellular Endocrinology.

Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells.

S. Lamberts, B. Löwenberg, I. Touw, 2002, Experimental hematology.

Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).

A. Hagenbeek, F. Rutten, B. Löwenberg, 1995, Bone marrow transplantation.

Bone Marrow Transplan- tation: Biological Mechanisms and Clinical Practice

B. Löwenberg, D. V. Bekkum, 1985 .

Transplantation of fetal liver cells in the treatment of severe combined immunodeficiency disease

B. Löwenberg, J. Vossen, L. Dooren, 1977, Blut.

Transition of highly specific microRNA expression patterns in association with discrete maturation stages of human granulopoiesis

M. Jongen‐Lavrencic, S. Sun, S. Erkeland, 2011, British journal of haematology.

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies

Bob Löwenberg, Matthias Theobald, E. Vellenga, 2005, British journal of haematology.

Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes.

J. Bos, F. Dong, B. Löwenberg, 1996, Blood.

MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

P. Sonneveld, R. Pieters, B. van der Holt, 1997, British journal of haematology.

Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

P. Sonneveld, R. Pieters, J. Lankelma, 1999, Leukemia.

Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.

P. Sonneveld, E. Vellenga, A. Gratwohl, 2000, The hematology journal : the official journal of the European Haematology Association.

Acute myeloid leukemia and acute promyelocytic leukemia.

Bob Löwenberg, J. Griffin, M. Tallman, 2003, Hematology. American Society of Hematology. Education Program.

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

K. Wagner, M. Heuser, F. Thol, 2011, Blood.

ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients

P. Sonneveld, E. Wiemer, R. V. van Schaik, 2006, Clinical pharmacology and therapeutics.

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

M. Höglund, B. van der Holt, B. Löwenberg, 2003, Experimental hematology.

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

K. Döhner, R. Schlenk, H. Döhner, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leukemic karyotype in CFU-C of a patient with acute myelomonocytic leukemia.

A. Hagemeijer, B. Löwenberg, 1983, The New England journal of medicine.

Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value

Bob Löwenberg, Mathijs A Sanders, M. Sanders, 2012, Haematologica.

A method for cloning T‐lymphocytic precursors in agar

B. Löwenberg, H. de Zeeuw, 1979, American journal of hematology.

Incomplete chimerism in erythroid, myeloid and B lymphocyte lineage after T cell-depleted allogeneic bone marrow transplantation.

A. Hagenbeek, B. Löwenberg, H. Schouten, 1988, Bone marrow transplantation.

MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia.

M. Manz, B. Löwenberg, Hitoshi Takizawa, 2016, Blood.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

E. Vellenga, F. Baron, G. Meloni, 2016, Leukemia.

Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia

A. Hagenbeek, B. Löwenberg, M. Oudshoorn, 2002, Bone Marrow Transplantation.

PCN1 COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA

A. Hagenbeek, B. Löwenberg, M. Oudshoorn, 2002 .

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.

Marcel J T Reinders, Erdogan Taskesen, Yvette van Norden, 2014, Blood.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

A. Ganser, S. Schrier, F. Lo‐Coco, 2017, Blood advances.

GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF

A. Hagenbeek, I. Touw, B. Löwenberg, 1998, Leukemia.

The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.

L. Bullinger, K. Döhner, R. Schlenk, 2013, Blood.

Effects of human interleukin-3 on granulocytic colony-forming cells in human bone marrow.

P. Schipper, B. Löwenberg, L. V. van Eijk, 1989, Blood.

Induction of proliferation of haemopoietic stem cells in culture.

B. Löwenberg, K. Dicke, 1977, Experimental hematology.

with acute myeloid leukemia ) is associated GFI1 ( Growth Factor Independence 1 A variant allele of

K. Grzeschik, T. Möröy, M. Slovak, 2010 .

Acute myeloid leukemia colony growth in vitro: differences of colony-forming cells in PHA-supplemented and standard leukocyte feeder cultures.

A. Hagemeijer, B. Löwenberg, K. Swart, 1982, Blood.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

A. Ganser, S. Schrier, F. Lo‐Coco, 2014, Annals of Hematology.

T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem cell transplants

C. Lamers, J. Gratama, B. Löwenberg, 2006, Bone Marrow Transplantation.

The impact of CD4+Foxp3+ Treg on immunity to murine cytomegalovirus after bone marrow transplantation depends on the peripheral or thymic source of T cell regeneration.

E. Wils, B. Löwenberg, J. Cornelissen, 2010, Transplant immunology.

Criteria for complete remission in acute myeloid leukemia revisited.

E. Vellenga, W. V. Putten, B. Löwenberg, 2003 .

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

H. Döhner, S. Choe, H. Kantarjian, 2020, Blood.

Brief Report Results and Discussion

Bas J. Wouters, W. van Putten, B. Löwenberg, 2022 .

Allogeneic bone marrow transplantation in patients with multiple myeloma

M. Gore, G. Gahrton, A. Gratwohl, 1989, European journal of haematology. Supplementum.

2 receptors, and interleukin 2 stimulates in vitro colony formation Common and pre-B acute lymphoblastic leukemia cells express interleukin

B. Löwenberg, I. Touw, R. Delwel, 2011 .

A comparison of in vitro sensitivity of acute myeloid leukemia precursors to mitoxantrone, 4'deoxydoxorubicin, 4-demethoxydaunorubicin and daunorubicin.

C. Schölzel, W. van Putten, B. Löwenberg, 1986, Leukemia research.

Detection of the blastic crisis cell clone in chronic myeloid leukaemia

A. Hagemeijer, B. Löwenberg, J. Abels, 1985, British journal of haematology.

Autologous Bone Marrow Transplantation in Patients with AML without Tumor Cell Purging and Post Transplant Chemotherapy

A. Hagenbeek, G. Wagemaker, B. Löwenberg, 1984 .

Studies on chronic myeloid leukemia cell populations with colony-forming abilities in PHA-leukocyte feeder and Robinson assays.

A. Hagemeijer, B. Löwenberg, K. Swart, 1982, Leukemia research.

Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.

R. Willemze, B. Löwenberg, R. Zittoun, 1988, European journal of cancer & clinical oncology.

Human AML colony growth in serum-free culture.

I. Touw, B. Löwenberg, I. Touw, 1988, Leukemia research.

The human GFI136N variant induces epigenetic changes at the Hoxa9 locus and accelerates K-RAS driven myeloproliferative disorder in mice.

E. Diamanti, T. Möröy, J. Schütte, 2012, Blood.

Autologous stem-cell transplantation and purging.

B. Löwenberg, P. Voogt, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice.

P. Sharp, Jeroen A. A. Demmers, P. Stern, 2011, Blood.

High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

K. Döhner, R. Schlenk, H. Döhner, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation.

L. Hoefsloot, F. Dong, B. Löwenberg, 1996, Blood.

Dynamics of Protein Binding to Telomeres in Living Cells: Implications for Telomere Structure and Function

A. Houtsmuller, A. Nigg, B. Löwenberg, 2004, Molecular and Cellular Biology.

Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice

D. Meijer, B. Löwenberg, R. Delwel, 2000, Leukemia.

High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

A. Ganser, S. Schrier, F. Lo‐Coco, 2015, Blood.

Involvement of tumor necrosis factor (TNF) receptors p55 and p75 in TNF responses of acute myeloid leukemia blasts in vitro

B. Löwenberg, I. Touw, R. Delwel, 1992 .

Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia.

Bob Löwenberg, Ruud Delwel, R. Verhaak, 2006, Cancer research.

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia.

W. Kamps, M. D. Den Boer, C. Zwaan, 2010, Blood.

The Development and Validation of a Decision-Analytic Model Representing the Full Disease Course of Acute Myeloid Leukemia

B. Löwenberg, C. U. Uyl‐de Groot, W. Redekop, 2013, PharmacoEconomics.

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012

P. Sonneveld, M. Jongen‐Lavrencic, G. Ossenkoppele, 2016, Leukemia.

The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood

C. Craddock, M. Labopin, P. Chevallier, 2014 .

Various Other 3 q Abnormalities in Acute Myeloid Leukemia

K. Döhner, R. Schlenk, H. Döhner, 2010 .

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.

Veronika Rockova, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

Stimulating spectrum of human recombinant multi-CSF (IL-3) on human marrow precursors: importance of accessory cells.

L. Dorssers, G. Wagemaker, B. Löwenberg, 1988, Blood.

Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients.

A. Hagenbeek, B. Löwenberg, W. Sizoo, 1987, The Journal of infectious diseases.

Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: A method analysis

P. Sonneveld, B. Löwenberg, K. Nooter, 1986, Cancer Chemotherapy and Pharmacology.

Pap tests may detect other cancers

J. Reed, B. Löwenberg, 2013 .

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

E. Vellenga, M. Jongen‐Lavrencic, J. Passweg, 2017, Blood.

Impaired health‐related quality of life in acute myeloid leukemia survivors: a single‐center study

B. Löwenberg, C. U. Uyl‐de Groot, W. Redekop, 2014, European journal of haematology.

inhibitor tipifarnib in acute myeloid leukemia A 2-gene classifier for predicting response to the farnesyltransferase

Yixin Wang, P. Greenberg, R. Stone, 2008 .

Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas.

R. Valkema, E. Krenning, S. Lamberts, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia.

E. Estey, R. Levine, B. Löwenberg, 2015, Blood.

Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)

G. Ossenkoppele, B. Löwenberg, F. Termorshuizen, 2008 .

Gene expression profiling in acute myeloid leukemia

B. Löwenberg, R. Delwel, P. Valk, 2005, Current opinion in hematology.

MicroRNA-155 induces AML in combination with the loss of C/EBPA in mice

S. Erkeland, M. Sanders, R. Hoogenboezem, 2016, Leukemia.

Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture.

G. Wagemaker, B. Löwenberg, K. Lom, 1996, Blood.

Working Group (IWG) response criteria in myelodysplasia Clinical application and proposal for modification of the International

P. Greenberg, H. Kantarjian, J. Bennett, 2009 .

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and

P. Sonneveld, A. Hagemeijer, Z. Berneman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impaired iron uptake and transferrin binding by erythroblasts in the anaemia of rheumatoid arthritis.

B. Löwenberg, A. Swaak, G. Vreugdenhil, 1990, British journal of rheumatology.

Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis.

B. Löwenberg, A. Swaak, G. Vreugdenhil, 1990, Rheumatology international.

The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies

Marcel J. T. Reinders, Dick de Ridder, Frank J. T. Staal, 2006, BMC Bioinformatics.

Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.

P. Sonneveld, B. Löwenberg, K. Nooter, 1987, Haematology and blood transfusion.

The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells.

J. Jansen, B. Löwenberg, J. Marteijn, 2005, Blood.

prospective sibling donor versus no-donor comparison adult patients with acute lymphoblastic leukemia in first remission: a Myeloablative allogeneic versus autologous stem cell transplantation in

J. Baars, P. Sonneveld, G. Ossenkoppele, 2013 .

signature TRIADs : a new class of proteins with a novel cysteine-rich

B. V. D. Reijden, J. Jansen, B. Löwenberg, 1999 .

On the road to new drugs in acute myeloid leukemia.

Bob Löwenberg, B. Löwenberg, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse

M. Jongen‐Lavrencic, M. Sanders, B. Löwenberg, 2021, Leukemia.

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

T. Yau, S. Rutella, J. Dipersio, 2020, Blood advances.

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia

M. Minden, S. Rutella, J. Dipersio, 2019, Science Translational Medicine.

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

S. Rutella, J. Dipersio, S. Warren, 2018, Blood.

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

S. Rutella, J. Dipersio, J. Wigginton, 2018, Blood.

In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.

A. Hagenbeek, P. Sonneveld, B. Löwenberg, 1988, Leukemia.

INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia

M. Minden, L. Salmena, A. Hakem, 2015, Leukemia.

Keratinocyte Growth Factor Induces Expansion of Murine Peripheral CD4+Foxp3+ Regulatory T Cells and Increases Their Thymic Output1

B. Lambrecht, B. Löwenberg, J. Cornelissen, 2007, The Journal of Immunology.

Keratinocyte Growth Factor Induces Expansion of Murine Peripheral CD4 Foxp3 Regulatory T Cells and Increases Their Thymic Output

B. Lambrecht, B. Löwenberg, J. Cornelissen, 2007 .

Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML

M. Jongen‐Lavrencic, J. Passweg, T. Pabst, 2017 .

High-dose methotrexate with leucovorin rescue: effectiveness in relapsed hairy cell leukemia.

A. Hagenbeek, B. Löwenberg, P. Joosten, 1985, Blood.

[Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system].

M. J. van den Bent, B. Löwenberg, G. Bos, 1998, Nederlands tijdschrift voor geneeskunde.

Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia

G. Ossenkoppele, B. Löwenberg, M. Boogaerts, 1997, Stem cells.

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort

E. Haralambieva, R. Grobholz, C. B. Rudolf, 2021, Annals of Hematology.

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

S. Rutella, J. Dipersio, Catherine Lai, 2020, bioRxiv.

Fucose binding lectin for characterizing acute myeloid leukemia progenitor cells.

I. Touw, B. Löwenberg, I. Touw, 1986, Blood.

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

C. Viero, J. Dipersio, J. Wigginton, 2018, Blood.

Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients.

W. Hiddemann, J. Gerss, W. Berdel, 2012, Blood.

profile that is uniquely associated with a favorable outcome subgroup of acute myeloid leukemia with a distinctive gene expression mutations, define a CEBPA mutations, but not single CEBPA Double

B. Löwenberg, W. Putten, J. Peter, 2009 .

Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study.

P. Sonneveld, R. Willemze, B. Löwenberg, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study.

P. Sonneveld, W. van Putten, B. Löwenberg, 1990, Haematology and blood transfusion.

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

K. Metzeler, S. Bohlander, C. Buske, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.

E. Vellenga, F. Rutten, B. Löwenberg, 1998, British journal of haematology.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

E. Vellenga, J. Passweg, T. Pabst, 2015, The Lancet. Haematology.

Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

E. Havrdová, R. Clark, A. Steck, 2006, Multiple sclerosis.

Resistance to chemotherapy in acute leukemia

P. Sonneveld, B. Löwenberg, 1998, Current opinion in oncology.

Effects of recombinant multi-CSF, GM-CSF, G-CSF and M-CSF on the proliferation and maturation of human AML in vitro.

B. Löwenberg, R. Delwel, M. Salem, 1988, Blood cells.

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

S. Rutella, J. Dipersio, M. Jongen‐Lavrencic, 2020 .

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG

E. Estey, F. Appelbaum, M. Vekemans, 2015, Haematologica.

Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials

M. Vignetti, F. Mandelli, G. Leone, 2013 .

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia

P. Vyas, J. Bourhis, C. Craddock, 2018, Journal of internal medicine.

Allogeneic bone marrow transplantation for chronic myelogenous leukemia

A. Hagenbeek, B. Löwenberg, P. Anker, 1993 .

Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line

A. Hagemeijer, G. Wagemaker, B. Löwenberg, 1997, Leukemia.

Homogeneous antibodies in lethally irradiated and autologous bone marrow reconstituted Rhesus monkeys

B. Löwenberg, A. Swart, J. Radl, 1976 .

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

A. Ganser, F. Lo‐Coco, E. Vellenga, 2015, Annals of Hematology.

LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY

T. Pabst, G. Schuurhuis, M. Manz, 2017 .

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2009 .

Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system.

G. Wagemaker, S. Clark, B. Löwenberg, 1988, Blood.

Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia

David C. Atkins, Bob Löwenberg, David Atkins, 2007, Clinical Cancer Research.

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

P. Sonneveld, E. van den Berg, B. van der Holt, 2007, British journal of haematology.

Variable differentiation of human acute myeloid leukaemia during colony formation in vitro: a membrane marker analysis with monoclonal antibodies

B. Löwenberg, I. Touw, 1985, British journal of haematology.

AML Cell Heterogeneity. Implications for Leukemia Cell Separation from Autologous Bone Marrow Grafts

B. Löwenberg, J. Bauman, 1984 .

Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.

A. Hagenbeek, P. Sonneveld, B. Löwenberg, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G‐CSF

B. Löwenberg, P. Colombat, V. Santini, 1991, British journal of haematology.

FATAL CEREBRAL TOXOPLASMOSIS IN A BONE MARROW TRANSPLANT RECIPIENT WITH LEUKEMIA

B. Löwenberg, J. Gijn, A. Polderman, 1983, Transplantation.

Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of leukemic human megakaryoblasts.

F. Herrmann, M. Brach, R. Mertelsmann, 1990, Blood.

Randomized P lacebo-Controll ed T rial o f G r anulocyte- M a crophage C olony-Stimulati ng F actor i n P atients W ith Chemotherapy-Rel ated F ebrile N e utropenia

E. Vellenga, B. Löwenberg, 1996 .

Strict infection control measures do not prevent clonal spread of coagulase negative staphylococci colonizing central venous catheters in neutropenic hemato-oncologic patients.

A. van Belkum, H. Verbrugh, J. Nouwen, 2003, FEMS immunology and medical microbiology.

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis

B. Gjertsen, B. Löwenberg, P. Valk, 2021, Molecular oncology.

Introduction to the review series on advances in acute myeloid leukemia (AML).

B. Löwenberg, J. Rowe, 2016, Blood.

A catalyst for change: the European cancer Patient's Bill of Rights.

J. Bergh, C. la Vecchia, M. Barbacid, 2014, The oncologist.

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

J. Armand, J. Drach, J. S. San Miguel, 2007, The oncologist.

Textbook of Malignant Haematology

D. Linch, B. Löwenberg, L. Degos, 1999 .

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome (vol 93, pg 1894, 2008)

G. Ossenkoppele, B. Löwenberg, M. Chamuleau, 2007 .

Maturation hierarchy of leukemic stem cells

B. Löwenberg, W. Terpstra, 1998, Stem cells.

Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates immature marrow precursors but no CFU-GM, CFU-G, or CFU-M.

P. Schipper, B. Löwenberg, L. V. van Eijk, 1989, Experimental hematology.

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

H. Döhner, S. Choe, M. Tallman, 2018, Blood.

The hematologic mission and scope of the Journal in 2013: Blood, a podium for clinical studies and a podium for experimental research in hematology.

B. Löwenberg, N. Berliner, 2013, Blood.

In Vitro Colony Forming Cells of Acute Lymphoblastic Leukemia: Analysis of 24 Cases with Recombinant Interleukin 2 as Growth Stimulus

B. Löwenberg, I. Touw, R. Delwel, 1986 .

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

K. Döhner, R. Schlenk, H. Döhner, 2008, Haematologica.

HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics

Peter J. van der Spek, Sebastiaan Horsman, Roel G. W. Verhaak, 2006, BMC Bioinformatics.

Role of interleukin-7 in the growth of acute lymphoblastic leukemia.

A. Hagemeijer, R. V. van Gurp, B. Löwenberg, 1990, Bone marrow transplantation.

Comparative analysis of IL-1 regulated and spontaneous growth of acute myeloid leukemia in vitro.

I. Touw, P. Schipper, T. V. van Agthoven, 1990, Bone marrow transplantation.

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.

A. Ganser, S. Schrier, F. Lo‐Coco, 2013, Blood.

and survival of APL cells PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation

B. Torbett, T. Haferlach, M. Tschan, 2013 .

Deconvolution Of Hematopoietic Stem/Progenitor Cell Signaling Predicts Inflammatory Niche Remodeling To Be A Determinant Of Tissue Failure And Outcome In Human AML

Meltem Yıldırım, M. Sanders, R. Hoogenboezem, 2023, bioRxiv.

Eosinophilia and granulocytic dysplasia terminating in acute myeloid leukaemia after 24 years

B. Löwenberg, J. Doorduijn, K. van Lom, 1996, British journal of haematology.

Modulation of colony stimulating factor-(CSF) dependent growth of acute myeloid leukemia by tumor necrosis factor.

I. Touw, B. Löwenberg, I. Touw, 1990, Leukemia.

gene expression signatures and their favorable prognostic significance association with other gene abnormalities and previously established in acute myeloid leukemia ( AML ) : ( NPM 1 ) Mutations in nucleophosmin

Maarten A. Bijl, A. Uitterlinden, R. Verhaak, 2005 .

prognostic significance association with other gene abnormalities and previously established gene Mutations in nucleophosmin NPM 1 in acute myeloid leukemia ( AML ) :

A. Uitterlinden, R. Verhaak, M. Sanders, 2005 .

A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.

G. Morgan, P. Sonneveld, F. Davies, 2007 .

Interleukin-3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF.

H. Burger, G. Wagemaker, B. Löwenberg, 1994, Experimental hematology.

MESNUM AND CYCLOPHOSPHAMIDE CYSTITIS

B. Löwenberg, J. Abels, J. Murray, 1980, The Lancet.

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

G. Ossenkoppele, B. Löwenberg, R. Delwel, 2008, Haematologica.

A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group

P. Sonneveld, W. V. Putten, B. Löwenberg, 1998, Leukemia.

High rates of molecular response and low incidence of mutations in patients treated with newly diagnosed chronic myeloid leukemia (CML) treated with a dose-escalated combination of imatinib and cytarabin.

H. Kluin-Nelemans, G. Ossenkoppele, B. Löwenberg, 2004 .

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

M. Jongen‐Lavrencic, T. Pabst, G. Ossenkoppele, 2023, Blood cancer journal.

Identification of Molecular Predictors of Response to ZARNESTRA™ (Tipifarnib, R115777) in Relapsed and Refractory Acute Myeloid Leukemia.

David C. Atkins, Yixin Wang, Yi Zhang, 2004 .

Strategies in the treatment of acute myeloid leukemia.

B. Löwenberg, 2004 .

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

S. Armstrong, H. Döhner, R. Koche, 2015 .

Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.

A. Ganser, R. Ribeiro, F. Lo Coco, 2019, Blood.

Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.

F. Lo‐Coco, R. Ribeiro, C. Niemeyer, 2009 .

Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.

G. Juliusson, J. Passweg, K. Porkka, 2023, Haematologica.

Heterogeneity of proliferative responses of human B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells to interleukin 7 (IL-7): no correlation with immunoglobulin gene status and expression of IL-7 receptor or IL-2/IL-4/IL-7 receptor common gamma chain genes.

I. Touw, B. Löwenberg, F. Smiers, 1995, Leukemia.

Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.

E. Estey, R. Hills, F. Appelbaum, 2013, Blood.

Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia

A. Ganser, F. Lo‐Coco, R. Ribeiro, 2020, Cancers.

University of Groningen Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia Weinhäuser,

A. Ganser, F. Lo‐Coco, R. Ribeiro, 2020 .

Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes.

A. Hagemeijer, B. Löwenberg, I. Touw, 1989, Leukemia research.

Ultrasound examination of pathological cervical lymph nodes in patients with non‐Hodgkin's lymphoma and Hodgkin's disease

B. Löwenberg, K. Lom, H. Adriaansen, 1994, British journal of haematology.

Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.

A. Hagenbeek, F. Rutten, B. Löwenberg, 1995, Bone marrow transplantation.

locus and accelerates K-RAS driven myeloproliferative disorder in mice Hoxa9 The human GFI136N variant induces epigenetic changes at the

E. Diamanti, T. Möröy, J. Schütte, 2013 .

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

E. Vellenga, M. Jongen‐Lavrencic, G. Ossenkoppele, 2017 .

Improved peripheral blood stem cell collection by GM-CSF stimulation in patients with multiple myeloma

A. Hagenbeek, B. Löwenberg, K. Sintnicolaas, 1990 .

[A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin].

H. Endtz, I. Gyssens, B. Löwenberg, 1995, Nederlands tijdschrift voor geneeskunde.

Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.

H. Kantarjian, G. Martinelli, P. Rousselot, 2009 .

leukemia Granulocyte colony-stimulating factor receptors in human acute myelocytic

B. Löwenberg, I. Touw, R. Delwel, 2011 .

ALLOGENEIC BONE MARROW TRANSPLANTATION FOR PRIMARY MYELOFIBROSIS

A. Hagenbeek, B. Löwenberg, G. Creemers, 1992, British journal of haematology.

Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia

R. Willemze, B. Löwenberg, J. Cornelissen, 2011, Leukemia.

Density profiles and purification of chronic myeloid leukemia cells forming colonies in the PHA-leukocyte feeder assay.

A. Hagemeijer, B. Löwenberg, K. Swart, 1981, Experimental Hematology.

The value of a 51Cr platelet lysis assay as crossmatch test in patients with leukaemia on platelet transfusion therapy

B. Löwenberg, K. Sintnicolaas, Ko J. Van Der Velden, 1986, British journal of haematology.

A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia: A leukemia‐lymphoma group trial of the EORTC

R. Willemze, C. Haanen, B. Löwenberg, 1986, Cancer.

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.

W Hop, H. V. D. Lelie, P. Sonneveld, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.

J. Raemaekers, A. Hagenbeek, P. Sonneveld, 1995, The New England journal of medicine.

A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies.

P. Sonneveld, P. Atadja, D. DeAngelo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays.

L. Bullinger, K. Döhner, H. Döhner, 2013, Genetic testing and molecular biomarkers.

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

J. Esteve, D. Colomer, Marcos González, 2008, Blood.

SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels

Sebastiaan Horsman, Bob Löwenberg, Mathijs A Sanders, 2008, BMC Genomics.

abnormal migration properties in a ligand-dependent manner blasts, either induces a neutrophilic differentiation block or confers The peripheral cannabinoid receptor Cb2, frequently expressed on AML

B. Löwenberg, M. Maccarrone, R. Delwel, 2011 .

IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and Enhances Survival against High-Dose Challenge1

H. Ochs, Jonathan D. Curtis, D. Rawlings, 2009, The Journal of Immunology.

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

J. Esteve, L. Escoda, E. Vellenga, 2018, Leukemia.

Role of arsenic trioxide in front-line therapy

F. Lo‐Coco, R. Ribeiro, M. Sanz, 2006 .

Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines.

B. Löwenberg, R. Delwel, H. Hoogerbrugge, 1993, Leukemia.

NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia

A. Ganser, F. Lo‐Coco, R. Ribeiro, 2020, Scientific Reports.

[Treatment of elderly patients with acute myeloid leukemia].

B. Löwenberg, 1997, Nederlands tijdschrift voor geneeskunde.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias

K. Döhner, R. Schlenk, H. Döhner, 2011 .

Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor.

J. Bos, B. Burgering, B. Löwenberg, 1998, Blood.

Keratinocyte Growth Factor Improves Allogeneic Bone Marrow Engraftment through a CD4+Foxp3+ Regulatory T Cell-Dependent Mechanism1

B. Löwenberg, J. Cornelissen, E. Braakman, 2009, The Journal of Immunology.

Allogeneic Bone Marrow Engraftment Keratinocyte Growth Factor Improves

B. Löwenberg, J. Cornelissen, E. Braakman, 2009 .

Analysis of the breakpoints in translocation (15;17) Observed in 4 patients with acute promyelocytic leukemia

A. Hagemeijer, B. Löwenberg, J. Abels, 1982, Human Genetics.

TRIADs: A new class of proteins with a novel cysteine‐rich signature

J. Jansen, B. Löwenberg, B. A. van der Reijden, 1999, Protein science : a publication of the Protein Society.

recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults:

C. Bloomfield, E. Estey, T. Naoe, 2010 .

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2010 .

in CD34+ acute myeloid leukemia cells Predominance of functional multidrug resistance (MDR-1) phenotype

P. Sonneveld, A. Hagemeijer, B. Löwenberg, 2011 .

Haploidentical ‘megadose’ stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings

N. Schmitz, M. Martelli, R. Mertelsmann, 2002, Leukemia.

Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

G. Juliusson, J. Passweg, K. Porkka, 2023, Blood.

K. Döhner, R. Schlenk, H. Döhner, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

W. van Putten, B. Löwenberg, S. Lugthart, 2010, Blood.

Therapeutic advances in acute myeloid leukemia.

B. Löwenberg, A. Burnett, M. Wetzler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

acute myeloid leukemia MicroRNA expression profiling in relation to the genetic heterogeneity of

M. Jongen‐Lavrencic, S. Sun, B. Löwenberg, 2013 .

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

W. Hiddemann, G. Lenz, G. Sauvageau, 2019, Leukemia.

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

E. Vellenga, T. Pabst, G. Ossenkoppele, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects.

Bas J. Wouters, B. Löwenberg, R. Delwel, 2009, Blood.

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

P. Sonneveld, H. Kantarjian, G. Martinelli, 2011, Blood.

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

P. Sonneveld, G. Ossenkoppele, G. Verhoef, 2003, Blood.

Leukemia Identification of Disease Genes in Human Acute Myeloid Significance of Murine Retroviral Mutagenesis for Updated

R. Verhaak, S. Erkeland, B. Löwenberg, 2006 .

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

V. V. D. van der Velden, M. Vekemans, J. Passweg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BONE MARROW TRANSPLANTATION STRATEGIES IN ACUTE LEUKAEMIA

A. Hagenbeek, B. Löwenberg, D. Maraninchi, 1984, The Lancet.

marrow precursors: importance of accessory cells Stimulating spectrum of human recombinant multi-CSF (IL-3) on human

G. Wagemaker, B. Löwenberg, L. Dorssers, 2011 .

Treatment of the elderly patient with acute myeloid leukaemia.

B. Löwenberg, B. Lt3WENBERG, 1996, Bailliere's clinical haematology.

Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.

P. Sonneveld, E. Vellenga, B. Löwenberg, 1996, Leukemia.